Clinical Trials | December 18, 2025
Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
The combination also outperformed chemotherapy on another important secondary endpoint
The combination also outperformed chemotherapy on another important secondary endpoint
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
Subscribe To Our Newsletter & Stay Updated
